UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: May 14, 2002
Cytomedix, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-28443 23-3011702
New address
Eden Tower Plaza, 790 Frontage Road, Northfield, Illinois 60093
Three Parkway North, Deerfield, Illinois 60015
(Former name or former address, if changed since last report)
Item 3.
An amended plan of reorganization has been submitted but has not yet been confirmed. See Item 5.
Item 5. Other Events
As reported in form 8-K filed on August 8, 2001, Cytomedix, Inc. (the "Company"), filed a voluntary petition for bankruptcy under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court of the Northern District of Illinois, Eastern Division (Case No. 01- 27610). The Court has named the Company as debtor in possession and the Company is authorized to continue to operate its business.
On March 21, 2002, the Company filed its Chapter 11 Reorganization Plan with the accompanying disclosure statement and a motion to approve the adequacy of the disclosure statement. On April 23, 2002, the Court approved the disclosure statement and related notices, established voting procedures and set the confirmation hearing date for June 6, 2002. See Order as Appendix G attached as Exhibit 2.15. On April 24, 2002, the Company filed its First Amended Plan of Reorganization with the accompanying disclosure statement.
The First Amended Plan of Reorganization and Disclosure Statement to the Plan of Reorganization and some of the exhibits thereto are included in this filing. Those Exhibits which either were submitted or will be submitted with the Proposed First Amended Plan and Disclosure Statement, but which are not included in this filing, are as follows: the Patent License Agreements, Schedule of Contracts to be Assumed, Schedule of Contracts to be Rejected, the Projected Balance Sheets and the Historical Financial Statements with Independent Auditors' Report. Any of these exhibits are available upon request to the Company at the name and address hereinabove stated. THIS PLAN HAS NOT YET BEEN CONFIRMED BY THE BANKRUPTCY COURT.
Item 7. Financial Statements and Exhibits
| Exhibit Number | Description of Exhibit |
| 2.01 | Proposed Amended Disclosure Statement to the First Amended Plan of Reorganization |
| 2.02_AppA | Appendix A to the Proposed First Amended Disclosure Statement to the Plan of Reorganization |
| 2.03_IA61 | Proposed Long-Term Incentive Plan (filed with 8-K on April 8, 2002) |
| 2.04_IA64 | Proposed Class A Warrant (filed with 8-K on April 8, 2002) |
| 2.05_IA65 | Proposed Class B Warrant (filed with 8-K on April 8, 2002) |
| 2.06_IA70 | Proposed Stock Certificate for Series A Convertible Preferred Stock (filed with 8-K on April 8, 2002) |
| 2.07_IA71 | Proposed Stock Certificate for Series B Convertible Preferred Stock (filed with 8-K on April 8, 2002) |
| 2.08_IA91 | Proposed Restated Bylaws (filed with 8-K on April 8, 2002) |
| 2.09_IA92A | Proposed Restated Certificate of Incorporation (filed with 8-K on April 8, 2002) |
| 2.10_IA92B | Proposed Restated Certificate of Designation (filed with 8-K on April 8, 2002) |
| 2.11_IA100 | Proposed Short Selling Bar Representation (filed with 8-K on April 8, 2002) |
| 2.12_AppD | Liquidation Analysis |
| 2.13_AppE | Information regarding the Certain Anticipated Officers, Directors and Consultants of the Reorganized Debtor |
| 2.14_AppF | List of Potential Defendants in Causes of Action for Infringement or Unauthorized Use of Intellectual Property Assets or Breaches of Confidentiality, Nondisclosure or Noncompetition Agreements |
| 2.15_AppG | Order |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cytomedix, Inc.
By: /s/Kent Smith
Chief Executive Officer/President
Date: May 14, 2002
